VNDA
Income statement / Annual
Last year (2025), Vanda Pharmaceuticals Inc's total revenue was $216.11 M,
an increase of 8.72% from the previous year.
In 2025, Vanda Pharmaceuticals Inc's net income was -$220.47 M.
See Vanda Pharmaceuticals Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$216.11 M |
$198.77 M |
$192.64 M |
$254.38 M |
$268.68 M |
$248.17 M |
$227.19 M |
$193.12 M |
$165.08 M |
$146.02 M |
| Cost of Revenue |
$13.04 M
|
$11.31 M
|
$14.80 M
|
$24.28 M
|
$25.63 M
|
$23.36 M
|
$24.49 M
|
$20.51 M
|
$17.85 M
|
$24.71 M
|
| Gross Profit |
$203.06 M
|
$187.46 M
|
$177.84 M
|
$230.10 M
|
$243.05 M
|
$224.80 M
|
$202.70 M
|
$172.61 M
|
$147.24 M
|
$121.31 M
|
| Gross Profit Ratio |
0.94
|
0.94
|
0.92
|
0.9
|
0.9
|
0.91
|
0.89
|
0.89
|
0.89
|
0.83
|
| Research and Development Expenses |
$109.27 M
|
$74.43 M
|
$76.82 M
|
$85.77 M
|
$75.36 M
|
$55.58 M
|
$48.65 M
|
$43.59 M
|
$38.55 M
|
$29.16 M
|
| General & Administrative Expenses |
$0.00
|
$144.51 M
|
$112.38 M
|
$133.89 M
|
$117.35 M
|
$127.91 M
|
$126.54 M
|
$105.75 M
|
$122.54 M
|
$98.39 M
|
| Selling & Marketing Expenses |
$0.00
|
$1.90 M
|
$500.00 K
|
$2.60 M
|
$6.70 M
|
$12.60 M
|
$3.20 M
|
$0.00
|
$1.30 M
|
$1.40 M
|
| Selling, General & Administrative Expenses |
$237.95 M
|
$146.41 M
|
$112.88 M
|
$136.49 M
|
$124.05 M
|
$140.51 M
|
$129.74 M
|
$105.75 M
|
$123.84 M
|
$99.79 M
|
| Other Expenses |
$7.01 M
|
$7.27 M
|
$2.09 M
|
$1.52 M
|
$1.48 M
|
$1.48 M
|
$1.51 M
|
$3.61 M
|
$1.47 M
|
$665.00 K
|
| Operating Expenses |
$354.23 M
|
$228.12 M
|
$191.80 M
|
$223.77 M
|
$200.89 M
|
$197.57 M
|
$179.89 M
|
$150.87 M
|
$164.14 M
|
$139.88 M
|
| Cost And Expenses |
$367.27 M
|
$239.43 M
|
$206.59 M
|
$248.05 M
|
$226.52 M
|
$220.93 M
|
$204.38 M
|
$171.38 M
|
$181.99 M
|
$164.59 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$199.00 K
|
$4.42 M
|
$6.22 M
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$11.92 M
|
$8.13 M
|
$3.01 M
|
$2.73 M
|
$2.84 M
|
$2.86 M
|
$2.89 M
|
$2.96 M
|
$2.98 M
|
$11.87 M
|
| EBITDA |
-$139.25 M |
-$32.53 M |
-$10.94 M |
$9.06 M |
$45.01 M |
$34.52 M |
$25.70 M |
$24.69 M |
-$13.92 M |
-$6.70 M |
| EBITDA Ratio |
-0.64
|
-0.16
|
-0.06
|
0.04
|
0.17
|
0.14
|
0.11
|
0.13
|
-0.08
|
-0.05
|
| Operating Income Ratio |
-0.7
|
-0.2
|
-0.07
|
0.02
|
0.16
|
0.11
|
0.1
|
0.11
|
-0.1
|
-0.13
|
| Total Other Income/Expenses Net |
$12.52 M
|
$17.74 M
|
$20.29 M
|
$4.97 M
|
$199.00 K
|
$4.42 M
|
$6.22 M
|
$3.61 M
|
$1.47 M
|
$665.00 K
|
| Income Before Tax |
-$138.65 M
|
-$22.92 M
|
$6.34 M
|
$11.30 M
|
$42.36 M
|
$31.66 M
|
$29.03 M
|
$25.35 M
|
-$15.43 M
|
-$17.91 M
|
| Income Before Tax Ratio |
-0.64
|
-0.12
|
0.03
|
0.04
|
0.16
|
0.13
|
0.13
|
0.13
|
-0.09
|
-0.12
|
| Income Tax Expense |
$81.83 M
|
-$4.02 M
|
$3.83 M
|
$5.03 M
|
$9.21 M
|
$8.32 M
|
-$86.53 M
|
$138.00 K
|
$136.00 K
|
$104.00 K
|
| Net Income |
-$220.47 M
|
-$18.90 M
|
$2.51 M
|
$6.28 M
|
$33.15 M
|
$23.34 M
|
$115.55 M
|
$25.21 M
|
-$15.57 M
|
-$18.01 M
|
| Net Income Ratio |
-1.02
|
-0.1
|
0.01
|
0.02
|
0.12
|
0.09
|
0.51
|
0.13
|
-0.09
|
-0.12
|
| EPS |
-3.74 |
-0.32 |
0.0437 |
0.11 |
0.6 |
0.43 |
2.17 |
0.5 |
-0.35 |
-0.41 |
| EPS Diluted |
-3.74 |
-0.32 |
0.0436 |
0.11 |
0.58 |
0.42 |
2.11 |
0.48 |
-0.35 |
-0.41 |
| Weighted Average Shares Out |
$58.93 M
|
$58.15 M
|
$57.38 M
|
$56.46 M
|
$55.55 M
|
$54.43 M
|
$53.14 M
|
$50.86 M
|
$44.48 M
|
$43.45 M
|
| Weighted Average Shares Out Diluted |
$58.93 M
|
$58.15 M
|
$57.56 M
|
$56.98 M
|
$56.92 M
|
$55.19 M
|
$54.85 M
|
$53.05 M
|
$44.74 M
|
$43.45 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
